Mirati Therapeutics Announces Departure Of CFO Laurie Stelzer On September 8; Aaron Ondrey To Assume Role Of Interim CFO
Portfolio Pulse from Benzinga Newsdesk
Mirati Therapeutics has announced that its CFO, Laurie Stelzer, will be leaving the company on September 8. Aaron Ondrey will take over as interim CFO.
August 23, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mirati Therapeutics' CFO, Laurie Stelzer, is leaving the company, with Aaron Ondrey stepping in as interim CFO. This could lead to short-term uncertainty for the company.
Changes in key management positions, such as the CFO, can lead to uncertainty among investors, potentially impacting the company's stock price in the short term. The impact of this news is highly relevant to MRTX as it directly involves the company's financial leadership.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100